Thirty years worth of data on outcomes with allogeneic hematopoietic cell transplant (allo-HCT) in patients with acute lymphoblastic leukemia (ALL) suggests that improvements have been seen over time. These data were published in Blood Advances.
“Over the past 30 years, remarkable developments have been made in both allo-HCT methods and treatments for ALL, which could improve patient outcomes,” the researchers explained in their report. However, they indicated, large-scale analyses of outcomes with allo-HCT in patients with ALL had not been conducted.
This retrospective analysis included patients 16 years of age or older in Japan who had undergone an initial allo-HCT for ALL from 1990 through 2019. Patients were grouped into time periods according to when allo-HCT was performed, including 1990 through 1999 (first decade), 2000 through 2009 (second decade), and 2010 through 2019 (third decade). The researchers examined trends over time for multiple outcomes in these patients, particularly in terms of survival trends and complete remission (CR) status.
A total of 1230 patients received allo-HCT in the first decade, 3012 patients received it in the second decade, and 4225 patients received it in the third decade. Median ages at the time of allo-HCT were 26 years for patients in the first decade, 37 years for patients in the second decade, and 43 years for patients in the third decade.
Among patients who experienced a first CR (CR1), the 5-year overall survival (OS) rate rose from 48.2% in the first decade to 70.2% in the third decade. For patients in a subsequent CR, the 5-year OS increased from 25.6% to 44.1%. Patients who did not have CR also showed an increase in 5-year OS, from 10.0% to 22.7%. Nonrelapse mortality was also reportedly improved over time for patients with CR1, subsequent CR, or non-CR status.
Relapse rates showed varied patterns by CR status over each decade of the study. For patients in CR1, the adjusted relapse rate changed from 26.4% in the first decade to 15.9% in the third decade. However, for patients with subsequent CR, the adjusted relapse rate changed only slightly, from 33.4% to 32.8%, from the first to the third decade. For patients without CR, this rate changed from 53.6% to 54.8%.
Patients with Philadelphia chromosome (Ph)-positive status appeared to show more substantial improvements in adjusted OS, leukemia-free survival (LFS), and relapse rates over time than patients with non-Ph disease. Although patients with non-Ph disease did show survival improvements, those with t(4;11), t(8;14), t(14;18), or haplodiploid features did not show consistent OS or LFS improvements over time.
Across the 3 decades included in this study, patients with ALL showed improved allo-HCT outcomes over time, but with apparent variation in certain subgroups, the researchers concluded. “Given that the improvement in allo-HCT outcomes for patients with high-risk chromosomal abnormalities were inadequate, it is desirable to develop targeted strategies to improve allo-HCT outcomes for those patients,” the researchers wrote.
Nishiwaki S, Akahoshi Y, Morita-Fujita M, et al; for the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Transplantation and Cellular Therapy. Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. Blood Adv. 2022;6(15):4558-4569. doi:10.1182/bloodadvances.2022008032
This article originally appeared on Hematology Advisor